Q-omics provides the consensus-scored RNF126 profile across patient tissues and cancer cell-line models. RNF126 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF126 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RNF126 protein abundance shows 19,494 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RNF126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF126 survival associations across molecular data types. RNF126 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF126 RNA expression–survival associations across cancer types. High RNF126 expression shows unfavorable associations in ACC, KICH, LUAD and LIHC, but favorable associations in SCLC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNF126 RNA expression.
This table summarizes RNF126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF126 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, STAD and KIRP. The KIRC box plot shows higher RNF126 RNA expression in tumor versus normal tissue (log2 FC = +0.871, t-test p < 0.001).
This table shows molecular features associated with RNF126 in patient tissues and cancer cell lines. In patient samples, RNF126 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF126 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
